Century Therapeutics, Inc.
3675 Market Street, Suite 200
Philadelphia
PA
19104
United States
Website: https://www.centurytx.com/contact-us/
About Century Therapeutics, Inc.
At Century, we are harnessing the power of adult stem cells to develop best-in-class allogeneic iNK and iT cell therapies for cancer. Century Therapeutics is an innovative biotechnology company that is building an industry leading allogeneic iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development, and manufacturing capabilities to generate allogeneic, iPSC-derived NK and T cell therapies for both hematological and solid tumor malignancies with significant unmet medical need. To achieve our mission, we are recruiting talented employees with diverse skills and subject matter expertise in order to achieve our scientific and business goals.
Together, we can change the future of cancer care by developing novel curative therapies for patients in need. We are One Century.
Offices in:
• Philadelphia, PA – Corporate Headquarters
• Branchburg, NJ – Our new facility to support the development of novel allogeneic living drugs for oncology treatment
COMPANY MISSION & VALUES
We are “One Century” and we’re on an important journey together to transform the future of cancer treatment. In pursuit of our mission, we firmly adhere to and are driven by our values.
• Integrity
• Passion
• Science
• Courage
CENTURY AT WORK, CENTURY AT PLAY
We believe in balance. We work hard every day to advance innovative immune cell therapies to meet the critical needs of the patients we aim to serve. Our work is driven by revolutionary ideas – not titles – and we value contributions from all. We have assembled a highly productive team that enjoys rigorous innovation and spending time together. If this sounds like an environment in which you would thrive, click the link below to view our current openings.
Stock Exchange: NASDAQ
Stock Symbol: IPSC
CONNECT
Century Therapeutics Inc. is an Equal Employment Opportunity/Affirmative Action Employer - Minority/Female/Disability/Veteran. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability, age, or veteran status or any other characteristic protected by federal, state, or local law. Please note Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites) or require potential candidates to make purchases of goods or services.
57 articles about Century Therapeutics, Inc.
-
BioSpace Movers & Shakers, May 7
5/7/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Century Therapeutics Expands Board of Directors with Key Appointments
5/5/2021
Pharmaceutical industry veteran Joe Jimenez appointed Board Chair Cynthia Butitta joins as Independent Director
-
Money on the Move – March 3-9
3/10/2021
Money flows into life sciences companies on a daily basis. Here’s who’s celebrating this week. -
Century Therapeutics Completes $160 Million Series C Financing to Accelerate Development of iPSC-derived Cell Therapy Pipeline
3/3/2021
Financing led by Casdin Capital and joined by Fidelity Management & Research LLC, the Federated Hermes Kaufmann Funds, RA Capital, Logos Capital, OrbiMed, Marshall Wace, Qatar Investment Authority, Avidity Partners, Octagon Capital, and joined by founding investors Versant Ventures and Leaps by Bayer Capital to expand novel iPSC platform and drive product development
-
Century Therapeutics received a $160 million infusion of cash to advance the company’s pipeline of induced pluripotent stem cell (iPSC)-derived cell therapies for cancer.
-
Century Therapeutics Significantly Expands Capabilities with New Operational, Laboratory and Manufacturing Facilities in Pennsylvania and New Jersey
2/17/2021
Century Therapeutics announced a significant expansion of its operational and laboratory space in Philadelphia, as well as progress on its manufacturing facility in Branchburg, NJ, paving the way for a strong technical foundation as the company scales up its in-house research and development capabilities.
-
BioSpace Movers & Shakers, Sept. 18
9/18/2020
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers. -
Century Therapeutics Announces Appointment of Michael C. Diem as Chief Business Officer
9/16/2020
Century Therapeutics , developer of induced pluripotent stem cell (iPSC)-derived allogeneic cell therapies for cancer, today announced the appointment of Michael C. Diem, MD, as Chief Business Officer. Dr. Diem has more than 15 years of experience in the global pharmaceutical and biotech industries and nearly 10 years of experience in academic and clinical medicine. “I am excited to welcome Mike to Century as he shar
-
Century Therapeutics Announces Acquisition of Empirica Therapeutics
6/23/2020
Century Therapeutics Canada will develop induced pluripotent Stem Cell (iPSC)-derived allogeneic immune cell therapies against glioblastoma (GBM)
-
Century Therapeutics Announces Formation of Scientific Advisory Board
5/5/2020
Century Therapeutics, developer of induced pluripotent stem cell -derived allogeneic cell therapies for cancer, announced the formation of its Scientific Advisory Board to include several renowned experts in the fields of developmental and stem cell biology, genetics, and immuno-oncology.
-
Century Therapeutics Announces Opening of Seattle Innovation Hub
3/10/2020
New company site will focus on creating next-gen product candidates to break barriers in the treatment of solid tumors
-
BioSpace Movers and Shakers, Jan. 31
1/31/2020
Pharma and biotech companies strengthen their leadership teams and boards with this week's Movers & Shakers. -
Century Therapeutics Expands Board of Directors and Management Team
1/28/2020
Century Therapeutics, a Versant Ventures-founded developer of next-generation allogeneic cell therapies, today announced the appointments of Joseph Jimenez to its board of directors and Greg Russotti, PhD, as chief technology officer.
-
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
-
Century Therapeutics Launches With USD 250M Financing for Induced Pluripotent Stem Cell (iPSC) Allogeneic Cell Therapy Platform - July 1, 2019
7/1/2019
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies
-
Century Therapeutics launches with USD 250M financing for induced pluripotent stem cell (iPSC) allogeneic cell therapy platform
7/1/2019
Created by Versant Ventures and partnered with Fujifilm to develop iPSC-derived adaptive and innate immune effector cell therapies
-
Century’s iPSCs, which are stem cells that can be generated from adult stem cells, have unlimited self-renewing capacity, the company said, which enables multiple rounds of cellular engineering.